BIOTECHNOLOGY INNOVATION ORGANIZATION for BIOTECHNOLOGY INNOVATION ORGANIZATION

Health Issues HCR

21st Century Cures Act 2.0 ---RFI from House Energy and Commerce Committee 340B Drug Discount Program ---Program Implementation & Oversight Biodefense Research, Development and Procurement Issues (Nonfunding) ---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019 ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 ---Implementation of the Families First Coronavirus Response Act of 2020 Biosimilars ---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019 ---Biosimilar Copay ---Reimbursement Coronavirus (COVID-19) Pandemic ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.4100/S.1712: DISARM Act of 2019 ---H.R.7661: Coronavirus Emerging Growth Companies (EGC) Extension Act of 2020 ---H.R.8080: Health STATISTICS Act of 2020 ---S.4317: SAFE TO WORK Act ---COVID-19 Lessons Learned ---COVID-19 Pricing-Related Provisions ---COVID-19 Vaccine Distribution ---Drug Supply Chain Management ---Immunization information systems ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 ---Implementation of the Families First Coronavirus Response Act of 2020 ---In-Home Administration of Part B Drugs ---Operation Warp Speed ---Patient Cost-Sharing and Smoothing ---PREP Act COVID-19 declaration coverage for private sector procurement ---Preventive Monoclonal Antibody Coverage Diversity & Inclusion Drug Evaluation and Review ---COVID-19 Lessons Learned ---Implementation of the Prescription Drug User Fee Act (PDUFA) VI ---Prescription Drug User Fee Act (PDUFA) VII Priorities ---Priority Review Voucher Programs Drug Importation ---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019 ---General Drug Manufacturing, Quality & Distribution ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.7767: To amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment ---Drug Shortages ---Executive Order on Buy American Drug Patenting ---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019 ---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019 ---H.R.3991: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 ---S.1416/H.R.4398/H.R.3991/H.R.5133: Affordable Prescriptions for Patients Act of 2019 ---S.1617: Second Look at Drug Patents Act of 2019 Drug Pricing ---H.R.3: Lower Drug Costs Now Act of 2019 ---H.R.19/S.3129: Lower Costs, More Cures Act of 2019 ---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019 ---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019 ---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019 ---H.R.1425: The Patient Protection and Affordable Care Enhancement Act of 2020 ---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019 ---H.R.3991: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 ---S.1416/H.R.4398/H.R.3991/H.R.5133: Affordable Prescriptions for Patients Act of 2019 ---S.1617: Second Look at Drug Patents Act of 2019 ---CMMI Authority ---COVID-19 Pricing-Related Provisions ---Executive Order on Lowering Drug Prices by Putting America First (Most Favored Nation, or MFN, EO) ---General ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 ---International Pricing Index Proposal ---Most Favored Nation (MFN) Model interim final rule (MFN Rule) Funding for Antimicrobial Resistance Programs ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---S.4760:Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020 ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---Funding for Strategic National Stockpile ---Health Defense Operations Funding Designation ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for FDA ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for Health Resources and Services Administration (HRSA) - Countermeasures Injury Compensation Program (CICP) ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act Funding for National Institutes of Health ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for the Centers for Disease Control and Prevention Vaccine Programs ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---Funding for 2020-21 Influenza Season Preparedness and Response ---Funding for Routine Immunization Infrastructure during Pandemic ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for the HHS Office of Infectious Disease and HIV/AIDS Policy ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act Medicaid ---H.R.5741: Strengthening Innovation in Medicare and Medicaid Act of 2020 ---S.3013: Encouraging Innovation Benefit Design to Lower Costs for Seniors Act of 2019 ---Alternative payment arrangements for gene therapies ---Average Manufacturer Price Calculations ---Drug Benefit Design ---Pricing and Rebates ---Value-Based Purchasing (VBP) Rule Orphan Drug Issues ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.4439/S.4010: Creating Hope Reauthorization Act of 2019 ---H.R.4712: Fairness in Orphan Drug Exclusivity Act of 2019 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act Rare Pediatric Disease Priority Review ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.4439/S.4010: Creating Hope Reauthorization Act of 2019 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act Reimbursement and Coverage of Innovative Products ---H.R.3: Lower Drug Costs Now Act of 2019 ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019 ---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.5741: Strengthening Innovation in Medicare and Medicaid Act of 2020 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---S.2326: New Opportunities for Value that Extend Lives (NOVEL) Act of 2019 ---Administration Rebate Rule ---CMMI Authority ---Executive Order on Increasing Drug Importation to Lower Prices for American Patients ---Executive Order on Lowering Drug Prices by Putting America First (Most Favored Nation, MFN EO) ---In-Home Administration of Part B Drugs ---International Pricing Index Proposal ---Medicare Part B Physician-Administered Products ---Patient Cost-Sharing and Smoothing ---Protected Classes ---Support of Patient Premiums and Cost-Sharing Obligations ---Value-Based Contracting and Communications ---Value-Based Purchasing (VBP) Rule The United States-Mexico-Canada Agreement (USMCA) ---Implementation of United States-Mexico-Canada Agreement (USMCA) ---IP Provisions US-China Trade Agreement ---IP Provisions US-UK Trade Agreement ---IP Provisions Vaccine Injury Compensation Program Tax ---H.R.1973/S.1654: Vaccine Access Improvement Act of 2019 Vaccines and Infectious Diseases ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.4100/S.1712: DISARM Act of 2019 ---H.R.5076/S.1872: Protecting Seniors through Immunizations Act of 2019 ---S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020 ---Adult Immunization Education ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 ---Implementation of the Families First Coronavirus Response Act of 2020 ---Maternal Immunization ---Operation Warp Speed ---Preventive Monoclonal Antibody Coverage ---Vaccine and Anti-Microbial Resistance Product Development and Incentives ---Vaccine Injury Compensation Program ---Vaccine Quality Measure ---Vaccine Safety

Contacted: Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); SENATE; Natl Economic Council (NEC); Commerce, Dept of (DOC); Patent & Trademark Office (PTO); Environmental Protection Agency (EPA); Securities & Exchange Commission (SEC); State, Dept of (DOS); Food & Drug Administration (FDA); Agriculture, Dept of (USDA); U.S. Trade Representative (USTR); Natl Institute of Standards & Technology (NIST); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); White House Office

Bills named: H.R. 1499 (116th), H.R. 488 (116th), H.R. 275 (116th), H.J.Res. 107 (116th), S. 1416 (116th), H.R. 7661 (116th), S. 4317 (116th), H.R. 4712 (116th), H.R. 19 (116th), H.R. 7767 (116th), H.R. 1046 (116th), H.R. 1973 (116th), S. 1712 (116th), S. 1617 (116th), S. 377 (116th), H.R. 8337 (116th), H.R. 5076 (116th), H.R. 4439 (116th), H.R. 1520 (116th), H.R. 1425 (116th), S. 2326 (116th), S. 1872 (116th), S. 1654 (116th), H.J.Res. 110 (116th), H.R. 5133 (116th), H.R. 4100 (116th), H.R. 133 (116th), H.R. 5741 (116th), H.R. 3991 (116th), H.R. 3 (116th), S. 4010 (116th), S. 3013 (116th), S. 3129 (116th), H.R. 8900 (116th), H.R. 4398 (116th), S. 4760 (116th), H.R. 8080 (116th), S. 99 (116th)

Agriculture AGR

Climate Change ---H.R.7393/S.3894: The Growing Climate Solutions Act of 2020 ---Fighting Climate Change through Biotechnology Innovation Coronavirus (COVID-19) Pandemic ---H.R.133: Consolidated Appropriations Act for FY 2021 ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 Foreign Agricultural Biotechnology Laws and Regulations ---EU Ag-Biotech Policies and Regulations ---Korea Biotechnology Regulations ---Mexico Draft Decree Banning Genetically Modified Corn ---Mexico Import Approval Delays of Ag Biotech Funding for the USDA ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act Genetically Engineered (GE) Animals ---FDA Proposed Guidance on Gene Editing ---GE Salmon language in Sec. 778 in H.R.133: Consolidated Appropriations Act for FY 2021 ---International Consistency of Regulation for Gene Edited Products ---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering Genetically Engineered (GE) Plants ---EPA proposed revisions to regulations related to the oversight of certain plant-incorporated protectants (PIPs) ---EPA Regulatory Approach to Gene Editing ---FDA Proposed Guidance on Gene Editing ---International Consistency of Regulation for Gene Edited Products Review and Labeling of Food Derived From Biotechnology ---Implementation of Disclosure Law The United States-Mexico-Canada Agreement (USMCA) ---Ag-Biotech Provisions US-China Trade Agreement ---Ag-Biotech Provisions US-UK Trade Agreement ---Ag-Biotech Provisions USDA/APHIS Agricultural Biotechnology Regulations ---Regulatory Treatment of Gene Edited Products ---Implementation of the SECURE Rule under the Plant Protection Act ---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering

Contacted: State, Dept of (DOS); Securities & Exchange Commission (SEC); Environmental Protection Agency (EPA); HOUSE OF REPRESENTATIVES; SENATE; Patent & Trademark Office (PTO); Food & Drug Administration (FDA); Natl Institute of Standards & Technology (NIST); Health & Human Services, Dept of (HHS); Natl Economic Council (NEC); Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); Agriculture, Dept of (USDA); Health Resources & Services Administration (HRSA); Commerce, Dept of (DOC); White House Office

Bills named: H.R. 8900 (116th), H.R. 7393 (116th), H.R. 1520 (116th), H.R. 133 (116th), H.J.Res. 110 (116th), H.R. 8337 (116th), H.J.Res. 107 (116th), S. 3894 (116th)

Trade (domestic/foreign) TRD

CFIUS and Foreign Investment ---Implementation of Foreign Investment Risk Review Modernization Act (FIRRMA) of 2017 Digital Trade ---EU Digital Strategy Drug Importation ---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019 ---General Drug Pricing ---Executive Order on Lowering Drug Prices by Putting America First (Most Favored Nation, or MFN, EO) ---International Pricing Index Proposal ---Most Favored Nation (MFN) Model interim final rule (MFN Rule) Foreign Agricultural Biotechnology Laws and Regulations ---EU Ag-Biotech Policies and Regulations ---Korea Biotechnology Regulations ---Mexico Draft Decree Banning Genetically Modified Corn ---Mexico Import Approval Delays of Ag Biotech Genetically Engineered (GE) Animals ---International Consistency of Regulation for Gene Edited Products Genetically Engineered (GE) Plants ---International Consistency of Regulation for Gene Edited Products Intellectual Property International Enforcement ---S.3952: A bill to require the imposition of sanctions with respect to foreign persons that have engaged in significant theft of trade secrets of United States persons, and for other purposes. ---India The United States-Mexico-Canada Agreement (USMCA) ---Ag-Biotech Provisions ---Implementation of United States-Mexico-Canada Agreement (USMCA) ---IP Provisions US-China Trade Agreement ---Ag-Biotech Provisions ---IP Provisions US-UK Trade Agreement ---Ag-Biotech Provisions ---IP Provisions ---Market Access World Health Organization (WHO) ---United States Withdrawal from the World Health Organization (WHO)

Contacted: White House Office; Patent & Trademark Office (PTO); Health & Human Services, Dept of (HHS); Natl Economic Council (NEC); Natl Institutes of Health (NIH); Health Resources & Services Administration (HRSA); Securities & Exchange Commission (SEC); Centers For Medicare and Medicaid Services (CMS); Environmental Protection Agency (EPA); Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Natl Institute of Standards & Technology (NIST); Agriculture, Dept of (USDA); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Bills named: H.R. 1046 (116th), S. 377 (116th), S. 3952 (116th)

Taxation/Internal Revenue Code TAX

Biofuels (Non-Funding) ---Incentives for Sustainable Aviation Fuels ---Sustainable Aviation Fuels Tax Credit Capital Formation Incentives ---H.R.7505: American Innovation Act of 2020 ---H.R.7537: Infectious Disease Therapies Research and Innovation Act ---H.R.7555: The More Cures Act of 2020 ---H.R.7556: Start-Ups for Cures Act ---H.R.7917: IGNITE American Innovation Act ---S.1249: American Innovation Act ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Families First Coronavirus Response Act of 2020 ---Introduction of IGNITE American Innovation in the Senate ---Proposed amendments under the Exchange Act of 1934 ---Proposed amendments under the Investment Company Act of 1940 ---Proposed amendments under the Securities Act of 1933 ---Reform of Net Operating Loss Rules ---Securities Regulations (13F, Exempt Offerings, Market Liquidity) Coronavirus (COVID-19) Pandemic ---H.R.7661: Coronavirus Emerging Growth Companies (EGC) Extension Act of 2020 ---H.R.7917: IGNITE American Innovation Act ---Introduction of IGNITE American Innovation in the Senate Research & Development Tax Credit Reforms ---H.R.4549: American Innovation and Competitiveness Act (AICA) of 2019 ---H.R.7767: To amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment. ---Expensing of R&D Expenditures ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 ---Implementation of the Families First Coronavirus Response Act of 2020 ---R&D Payroll Credit Vaccine Injury Compensation Program Tax ---H.R.1973/S.1654: Vaccine Access Improvement Act of 2019

Contacted: Natl Institute of Standards & Technology (NIST); State, Dept of (DOS); SENATE; Health Resources & Services Administration (HRSA); Securities & Exchange Commission (SEC); Patent & Trademark Office (PTO); Environmental Protection Agency (EPA); White House Office; Centers For Medicare and Medicaid Services (CMS); Agriculture, Dept of (USDA); Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); Natl Economic Council (NEC); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Commerce, Dept of (DOC)

Bills named: H.R. 7537 (116th), H.R. 1973 (116th), S. 1249 (116th), H.R. 7767 (116th), H.R. 4549 (116th), S. 1654 (116th), H.R. 7505 (116th), H.R. 7917 (116th), H.R. 7555 (116th), H.R. 7661 (116th), H.R. 7556 (116th)

Copyright/Patent/Trademark CPT

Bayh-Dole Act/Tech Transfer ---Bayh-Dole 40th Anniversary ---March-In Rights ---NIST Proposed Rulemaking on Bayh-Dole ---State Attorney General Letter Compulsory licensing ---H.R.465/S.102: Prescription Drug Price Relief Act of 2019 ---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019 ---S.2387: We Protect American Investment in Drugs Act of 2019 Diversity in Patenting ---S.4394: Inventor Diversity for Economic Advancement (IDEA) Act of 2020 Drug Patenting ---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019 ---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019 ---H.R.3991: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 ---S.1416/H.R.4398/H.R.3991/H.R.5133: Affordable Prescriptions for Patients Act of 2019 ---S.1617: Second Look at Drug Patents Act of 2019 Inter Partes Review Intellectual Property International Enforcement ---S.3952: A bill to require the imposition of sanctions with respect to foreign persons that have engaged in significant theft of trade secrets of United States persons, and for other purposes. ---India Patent Reform ---H.R.7259/S.2814: Patents for Humanity Program Improvement Act of 2020 ---Patent Litigation Reforms Patenting of Biological Inventions ---35 USC Section 101 on Patent Eligibility The United States-Mexico-Canada Agreement (USMCA) ---Implementation of United States-Mexico-Canada Agreement (USMCA) ---IP Provisions US-China Trade Agreement ---IP Provisions US-UK Trade Agreement ---IP Provisions

Contacted: Securities & Exchange Commission (SEC); Natl Institute of Standards & Technology (NIST); HOUSE OF REPRESENTATIVES; Natl Economic Council (NEC); White House Office; Environmental Protection Agency (EPA); Natl Institutes of Health (NIH); Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; Agriculture, Dept of (USDA); U.S. Trade Representative (USTR); State, Dept of (DOS); Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC)

Bills named: S. 2387 (116th), S. 377 (116th), S. 2814 (116th), S. 102 (116th), S. 3952 (116th), S. 1416 (116th), H.R. 4398 (116th), H.R. 7259 (116th), H.R. 1499 (116th), H.R. 465 (116th), H.R. 5133 (116th), H.R. 3991 (116th), H.R. 1046 (116th), S. 1617 (116th), S. 4394 (116th)

Small Business SMB

Capital Formation Incentives ---H.R.7505: American Innovation Act of 2020 ---H.R.7537: Infectious Disease Therapies Research and Innovation Act ---H.R.7555: The More Cures Act of 2020 ---H.R.7556: Start-Ups for Cures Act ---H.R.7917: IGNITE American Innovation Act ---S.1249: American Innovation Act ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Families First Coronavirus Response Act of 2020 ---Introduction of IGNITE American Innovation Act in Senate ---Proposed amendments under the Exchange Act of 1934 ---Proposed amendments under the Investment Company Act of 1940 ---Proposed amendments under the Securities Act of 1933 ---Reform of Net Operating Loss Rules Capital Market Enhancements ---Amended Definition of Smaller Reporting Company Coronavirus (COVID-19) Pandemic ---H.R.7661: Coronavirus Emerging Growth Companies (EGC) Extension Act of 2020 ---H.R.7917: IGNITE American Innovation Act ---Introduction of IGNITE American Innovation Act in Senate Coronavirus (COVID-19) Small Business Loans (Non-Funding) ---Affiliation ---Eligibility ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 Sarbanes Oxley Section 404 (b) ---H.R.3886/S.452: Fostering Innovation Act of 2019 ---Implementation of Jumpstart Our Business Startups (JOBS) Act of 2012 Small Business Innovation Research (SBIR) Program

Contacted: White House Office; Agriculture, Dept of (USDA); Environmental Protection Agency (EPA); Health & Human Services, Dept of (HHS); State, Dept of (DOS); Natl Institute of Standards & Technology (NIST); U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Health Resources & Services Administration (HRSA); Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Securities & Exchange Commission (SEC); Centers For Medicare and Medicaid Services (CMS); Natl Economic Council (NEC); Commerce, Dept of (DOC)

Bills named: H.R. 7537 (116th), H.R. 7555 (116th), S. 452 (116th), H.R. 7505 (116th), S. 1249 (116th), H.R. 3886 (116th), H.R. 7917 (116th), H.R. 7661 (116th), H.R. 7556 (116th)

Medicare/Medicaid MMM

21st Century Cures Act 2.0 ---RFI from House Energy and Commerce Committee Coronavirus (COVID-19) Pandemic ---H.R.4100/S.1712: DISARM Act of 2019 ---COVID-19 Pricing-Related Provisions ---Immunization information systems ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Families First Coronavirus Response Act of 2020 ---In-Home Administration of Part B Drugs ---Patient Cost-Sharing and Smoothing ---Preventive Monoclonal Antibody Coverage Drug Pricing ---H.R.3: Lower Drug Costs Now Act of 2019 ---H.R.19/S.3129: Lower Costs, More Cures Act of 2019 ---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019 ---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019 ---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019 ---S.1416/H.R.4398/H.R.3991/H.R.5133: Affordable Prescriptions for Patients Act of 2019 ---CMMI Authority ---COVID-19 Pricing-Related Provisions ---Executive Order on Lowering Drug Prices by Putting America First (Most Favored Nation, or MFN, EO) ---General ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 ---International Pricing Index Proposal ---Most Favored Nation (MFN) Model interim final rule (MFN Rule) Medicaid ---H.R.5741: Strengthening Innovation in Medicare and Medicaid Act of 2020 ---S.3013: Encouraging Innovation Benefit Design to Lower Costs for Seniors Act of 2019 ---Alternative payment arrangements for gene therapies ---Average Manufacturer Price Calculations ---Drug Benefit Design ---Pricing and Rebates ---Value-Based Purchasing (VBP) Rule Reimbursement and Coverage of Innovative Products ---H.R.3: Lower Drug Costs Now Act of 2019 ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019 ---H.R.488/S.99: Medicare Drug Price Negotiation Act of 2019 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.5741: Strengthening Innovation in Medicare and Medicaid Act of 2020 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---S.2326: New Opportunities for Value that Extend Lives (NOVEL) Act of 2019 ---Administration Rebate Rule ---CMMI Authority ---Executive Order on Lowering Drug Prices by Putting America First (Most Favored Nation, or MFN, EO) ---In-Home Administration of Part B Drugs ---International Pricing Index Proposal ---Medicare Part B Physician-Administered Products ---Most Favored Nation (MFN) Model interim final rule (MFN Rule) ---Patient Cost-Sharing and Smoothing ---Protected Classes ---Support of Patient Premiums and Cost-Sharing Obligations ---Value-Based Contracting and Communications ---Value-Based Purchasing (VBP) Rule Vaccines and Infectious Diseases ---H.R.5076/S.1872: Protecting Seniors through Immunizations Act of 2019

Contacted: HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Natl Institutes of Health (NIH); Environmental Protection Agency (EPA); Natl Economic Council (NEC); SENATE; Securities & Exchange Commission (SEC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); White House Office; Health Resources & Services Administration (HRSA); State, Dept of (DOS); Patent & Trademark Office (PTO); Agriculture, Dept of (USDA); Food & Drug Administration (FDA); Natl Institute of Standards & Technology (NIST)

Bills named: H.R. 8900 (116th), S. 1416 (116th), H.J.Res. 107 (116th), H.J.Res. 110 (116th), H.R. 8337 (116th), H.R. 5076 (116th), S. 1712 (116th), H.R. 4100 (116th), H.R. 19 (116th), S. 3013 (116th), S. 99 (116th), H.R. 1520 (116th), H.R. 4398 (116th), H.R. 3991 (116th), H.R. 488 (116th), S. 1872 (116th), H.R. 5741 (116th), S. 3129 (116th), H.R. 1046 (116th), H.R. 275 (116th), H.R. 5133 (116th), S. 377 (116th), H.R. 3 (116th), S. 2326 (116th)

Budget/Appropriations BUD

Coronavirus (COVID-19) Pandemic ---H.R.133: Consolidated Appropriations Act for FY 2021 ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 ---Implementation of the Families First Coronavirus Response Act of 2020 Funding for Antimicrobial Resistance Programs ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020 ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---Funding for Strategic National Stockpile ---Health Defense Operations Funding Designation ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for Biofuels ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---Incentives for Sustainable Aviation Fuels ---USDA Discretion to Provide Support for Biofuel Producers in H.R.133: Consolidated Appropriations Act for FY 2021 Funding for Biomass Crop Assistance Program ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act Funding for Biorefineries ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---USDA Discretion to Provide Support for Biofuel Producers in H.R.133: Consolidated Appropriations Act for FY 2021 Funding for FDA ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for Health Resources and Services Administration (HRSA) - Countermeasures Injury Compensation Program (CICP) ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act Funding for Health Resources and Services Administration (HRSA) - Vaccine Injury Compensation Program (VICP) ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act Funding for National Institutes of Health ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for Renewable Chemicals/Bio-based Products ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act Funding for the Centers for Disease Control and Prevention Vaccine Programs ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---Funding for 2020-21 Influenza Season Preparedness and Response ---Funding for Routine Immunization Infrastructure during Pandemic ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for the HHS Office of Infectious Disease and HIV/AIDS Policy ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act Funding for the USDA ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act

Contacted: Natl Economic Council (NEC); Health Resources & Services Administration (HRSA); SENATE; Food & Drug Administration (FDA); Natl Institute of Standards & Technology (NIST); Commerce, Dept of (DOC); State, Dept of (DOS); Securities & Exchange Commission (SEC); Natl Institutes of Health (NIH); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); White House Office; Agriculture, Dept of (USDA); Environmental Protection Agency (EPA); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR)

Bills named: H.J.Res. 110 (116th), H.J.Res. 107 (116th), S. 4760 (116th), H.R. 1520 (116th), H.R. 133 (116th), H.R. 8337 (116th), H.R. 8900 (116th)

Chemicals/Chemical Industry CHM

Funding for Renewable Chemicals/Bio-based Products ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act Renewable Chemicals/Bio-based Products (Non-Funding) ---H.R.2051/S.999: Sustainable Chemistry Research and Development Act of 2019 ---H.R.8879: Renewable Chemicals Act of 2020

Contacted: Securities & Exchange Commission (SEC); SENATE; State, Dept of (DOS); Food & Drug Administration (FDA); Agriculture, Dept of (USDA); Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); Natl Institutes of Health (NIH); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Natl Economic Council (NEC); HOUSE OF REPRESENTATIVES; Environmental Protection Agency (EPA); Commerce, Dept of (DOC); Natl Institute of Standards & Technology (NIST); Health Resources & Services Administration (HRSA); White House Office

Bills named: H.R. 133 (116th), H.J.Res. 107 (116th), H.R. 2051 (116th), H.R. 1520 (116th), H.R. 8879 (116th), H.R. 8900 (116th), H.J.Res. 110 (116th), S. 999 (116th), H.R. 8337 (116th)

Consumer Issues/Safety/Products CSP

Drug Importation ---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019 ---General Genetically Engineered (GE) Animals ---FDA Proposed Guidance on Gene Editing ---GE Salmon language in Sec. 778 in H.R.133: Consolidated Appropriations Act for FY 2021 ---International Consistency of Regulation for Gene Edited Products ---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering Review and Labeling of Food Derived From Biotechnology ---Implementation of Disclosure Law

Contacted: Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Securities & Exchange Commission (SEC); Environmental Protection Agency (EPA); Agriculture, Dept of (USDA); Health Resources & Services Administration (HRSA); Patent & Trademark Office (PTO); State, Dept of (DOS); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Natl Institute of Standards & Technology (NIST); White House Office; SENATE; Health & Human Services, Dept of (HHS); Natl Economic Council (NEC)

Bills named: H.R. 1046 (116th), S. 377 (116th), H.R. 133 (116th)

Energy/Nuclear ENG

Biofuels (Non-Funding) ---H.R.3006: Support RFS Integrity Act of 2019 ---H.R.7330: Growing Renewable Energy and Efficiency Now (GREEN) Act of 2020 ---H.R.8759: Streamlining Advanced Biofuels Registration Act of 2020 ---H.R.8769: The Sustainable Aviation Fuel Act ---S.3986: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes ---Incentives for Sustainable Aviation Fuels ---One-year extension of the Second-generation Biofuel Producer Tax Credit and Two-year Extension of the Section 45Q Credit for Carbon Dioxide Sequestration in H.R. 133: Consolidated Appropriations Act for FY 2021 ---Proposed Rule to set 2021 Renewable Volume Obligations (RVOs) under the Renewable Fuel Standard and the 2022 RVO for Biomass-based Diesel ---Small Refinery Waivers ---Sustainable Aviation Fuels Tax Credit Climate Change ---H.R.7393/S.3894: The Growing Climate Solutions Act of 2020 ---Fighting Climate Change through Biotechnology Innovation Funding for Biofuels ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---Incentives for Sustainable Aviation Fuels ---USDA Discretion to Provide Support for Biofuel Producers in H.R.133: Consolidated Appropriations Act for FY 2021 Funding for Biomass Crop Assistance Program ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act Funding for Biorefineries ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---USDA Discretion to Provide Support for Biofuel Producers in H.R.133: Consolidated Appropriations Act for FY 2021 RFS (Renewable Fuel Standard) ---H.R.3006: Support RFS Integrity Act of 2019 ---H.R.8759: Streamlining Advanced Biofuels Registration Act of 2020 ---S.3986: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes ---Cellulosic Registration Applications for Corn Kernel Fiber ---Proposed Rule to set 2021 Renewable Volume Obligations (RVOs) under the Renewable Fuel Standard and the 2022 RVO for Biomass-based Diesel ---RFS Reform ---Small Refinery Waivers

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Natl Institute of Standards & Technology (NIST); Commerce, Dept of (DOC); State, Dept of (DOS); Natl Economic Council (NEC); Health Resources & Services Administration (HRSA); Environmental Protection Agency (EPA); Natl Institutes of Health (NIH); U.S. Trade Representative (USTR); White House Office; Securities & Exchange Commission (SEC); Patent & Trademark Office (PTO); Agriculture, Dept of (USDA); SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 3006 (116th), H.R. 7330 (116th), H.R. 8900 (116th), H.R. 8337 (116th), H.J.Res. 110 (116th), H.R. 8759 (116th), S. 3894 (116th), H.J.Res. 107 (116th), H.R. 8769 (116th), S. 3986 (116th), H.R. 7393 (116th), H.R. 133 (116th), H.R. 1520 (116th)

Food Industry (safety, labeling, etc.) FOO

Genetically Engineered (GE) Animals ---FDA Proposed Guidance on Gene Editing ---GE Salmon language in Sec. 778 in H.R.133: Consolidated Appropriations Act for FY 2021 ---International Consistency of Regulation for Gene Edited Products ---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering Review and Labeling of Food Derived From Biotechnology ---Implementation of Disclosure Law USDA/APHIS Agricultural Biotechnology Regulations ---Regulatory Treatment of Gene Edited Products ---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering

Contacted: Agriculture, Dept of (USDA); HOUSE OF REPRESENTATIVES; White House Office; Environmental Protection Agency (EPA); Patent & Trademark Office (PTO); Natl Institutes of Health (NIH); Natl Institute of Standards & Technology (NIST); Natl Economic Council (NEC); Commerce, Dept of (DOC); SENATE; Food & Drug Administration (FDA); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); Health Resources & Services Administration (HRSA); Securities & Exchange Commission (SEC); Health & Human Services, Dept of (HHS)

Bills named: H.R. 133 (116th)

Animals ANI

Genetically Engineered (GE) Animals ---FDA Proposed Guidance on Gene Editing ---GE Salmon language in Sec. 778 in H.R.133: Consolidated Appropriations Act for FY 2021 ---International Consistency of Regulation for Gene Edited Products ---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering Review and Labeling of Food Derived From Biotechnology ---Implementation of Disclosure Law USDA/APHIS Agricultural Biotechnology Regulations ---Regulatory Treatment of Gene Edited Products ---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering

Contacted: Natl Institute of Standards & Technology (NIST); Food & Drug Administration (FDA); Securities & Exchange Commission (SEC); Commerce, Dept of (DOC); Natl Economic Council (NEC); SENATE; Agriculture, Dept of (USDA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); State, Dept of (DOS); Health Resources & Services Administration (HRSA); U.S. Trade Representative (USTR); White House Office; Environmental Protection Agency (EPA); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES

Bills named: H.R. 133 (116th)

Fuel/Gas/Oil FUE

Biofuels (Non-Funding) ---H.R.3006: Support RFS Integrity Act of 2019 ---H.R.7330: Growing Renewable Energy and Efficiency Now (GREEN) Act of 2020 ---H.R.8759: Streamlining Advanced Biofuels Registration Act of 2020 ---H.R.8769: The Sustainable Aviation Fuel Act ---S.3986: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes ---Incentives for Sustainable Aviation Fuels ---One-year extension of the Second-generation Biofuel Producer Tax Credit and Two-year Extension of the Section 45Q Credit for Carbon Dioxide Sequestration in H.R. 133: Consolidated Appropriations Act for FY 2021 ---Proposed Rule to set 2021 Renewable Volume Obligations (RVOs) under the Renewable Fuel Standard and the 2022 RVO for Biomass-based Diesel ---Small Refinery Waivers ---Sustainable Aviation Fuels Tax Credit Climate Change ---H.R.7393/S.3894: The Growing Climate Solutions Act of 2020 ---Fighting Climate Change through Biotechnology Innovation Funding for Biofuels ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---Incentives for Sustainable Aviation Fuels ---USDA Discretion to Provide Support for Biofuel Producers in H.R.133: Consolidated Appropriations Act for FY 2021 Funding for Biomass Crop Assistance Program ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act Funding for Biorefineries ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---USDA Discretion to Provide Support for Biofuel Producers in H.R.133: Consolidated Appropriations Act for FY 2021 RFS (Renewable Fuel Standard) ---H.R.3006: Support RFS Integrity Act of 2019 ---H.R.8759: Streamlining Advanced Biofuels Registration Act of 2020 ---S.3986: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes ---Cellulosic Registration Applications for Corn Kernel Fiber ---Proposed Rule to set 2021 Renewable Volume Obligations (RVOs) under the Renewable Fuel Standard and the 2022 RVO for Biomass-based Diesel ---RFS Reform ---Small Refinery Waivers

Contacted: U.S. Trade Representative (USTR); SENATE; Natl Institute of Standards & Technology (NIST); Patent & Trademark Office (PTO); Commerce, Dept of (DOC); Securities & Exchange Commission (SEC); Health Resources & Services Administration (HRSA); Agriculture, Dept of (USDA); Food & Drug Administration (FDA); Natl Economic Council (NEC); White House Office; Centers For Medicare and Medicaid Services (CMS); Environmental Protection Agency (EPA); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); State, Dept of (DOS)

Bills named: H.R. 8900 (116th), H.R. 7330 (116th), H.R. 8337 (116th), H.R. 3006 (116th), H.J.Res. 110 (116th), H.J.Res. 107 (116th), H.R. 8759 (116th), H.R. 8769 (116th), H.R. 133 (116th), H.R. 7393 (116th), S. 3986 (116th), H.R. 1520 (116th), S. 3894 (116th)

Homeland Security HOM

Biodefense Research, Development and Procurement Issues (Nonfunding) ---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019 ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 ---Implementation of the Families First Coronavirus Response Act of 2020 Funding for Antimicrobial Resistance Programs ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020 ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---Funding for Strategic National Stockpile ---Health Defense Operations Funding Designation ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

Contacted: Securities & Exchange Commission (SEC); Natl Institutes of Health (NIH); Patent & Trademark Office (PTO); Health Resources & Services Administration (HRSA); Agriculture, Dept of (USDA); Health & Human Services, Dept of (HHS); State, Dept of (DOS); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Environmental Protection Agency (EPA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Natl Institute of Standards & Technology (NIST); Commerce, Dept of (DOC); Natl Economic Council (NEC); SENATE; White House Office

Bills named: H.R. 133 (116th), H.R. 1520 (116th), H.R. 8337 (116th), H.J.Res. 107 (116th), S. 4760 (116th), H.R. 8900 (116th), H.J.Res. 110 (116th)

Medical/Disease Research/Clinical Labs MED

Biodefense Research, Development and Procurement Issues (Nonfunding) ---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019 ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 ---Implementation of the Families First Coronavirus Response Act of 2020 Coronavirus (COVID-19) Pandemic ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.7661: Coronavirus Emerging Growth Companies (EGC) Extension Act of 2020 ---H.R.8080: Health STATISTICS Act of 2020 ---COVID-19 Pricing-Related Provisions ---Drug Supply Chain Management ---Immunization information systems ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 ---Implementation of the Families First Coronavirus Response Act of 2020 ---In-Home Administration of Part B Drugs ---Patient Cost-Sharing and Smoothing ---Preventive Monoclonal Antibody Coverage Funding for Antimicrobial Resistance Programs ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2020 ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---Funding for Strategic National Stockpile ---Health Defense Operations Funding Designation ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for National Institutes of Health ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for the Centers for Disease Control and Prevention Vaccine Programs ---H.J.Res.107: Further Additional Continuing Appropriations Act of FY 2021 ---H.J.Res.110: Extension of Continuing Appropriations Act of FY 2021 ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1520: Further Extension of Continuing Appropriations Act of FY 2021 ---H.R.8337: The Continuing Appropriations Act for FY 2021 and Other Extensions Act ---H.R.8900: Further Continuing Appropriations Act for FY 2021, and Other Extensions Act ---Funding for 2020-21 Influenza Season Preparedness and Response ---Funding for Routine Immunization Infrastructure during Pandemic ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020

Contacted: HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Natl Institutes of Health (NIH); Food & Drug Administration (FDA); Environmental Protection Agency (EPA); SENATE; White House Office; U.S. Trade Representative (USTR); Agriculture, Dept of (USDA); Health & Human Services, Dept of (HHS); Securities & Exchange Commission (SEC); Patent & Trademark Office (PTO); Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); Natl Economic Council (NEC); Natl Institute of Standards & Technology (NIST); State, Dept of (DOS)

Bills named: H.R. 133 (116th), H.J.Res. 110 (116th), S. 4760 (116th), H.J.Res. 107 (116th), H.R. 8337 (116th), H.R. 1520 (116th), H.R. 8900 (116th), H.R. 8080 (116th), H.R. 7661 (116th)

Science/Technology SCI

Engineering Biology ---H.R.4373 Engineering Biology Research and Development Act ---S.3734: Bioeconomy Research and Development Act of 2020

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); Natl Institute of Standards & Technology (NIST); Natl Economic Council (NEC); Commerce, Dept of (DOC); White House Office; Health Resources & Services Administration (HRSA); Environmental Protection Agency (EPA); Securities & Exchange Commission (SEC); Agriculture, Dept of (USDA); State, Dept of (DOS); Natl Institutes of Health (NIH); SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 4373 (116th), S. 3734 (116th)